Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:ALZN NASDAQ:PASG NASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.91-0.5%$1.84$1.26▼$4.50$16.37M2.411.05 million shs25,851 shsALZNAlzamend Neuro$1.21+5.7%$1.08$0.84▼$3.60$4.36M0.1661,535 shs61,212 shsPASGPassage Bio$5.81+3.8%$6.51$3.93▼$20.00$17.96M1.4134,730 shs30,356 shsSNSESensei Biotherapeutics$13.00+20.5%$23.28$5.60▼$36.76$14.48M-0.2544,130 shs58,044 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+1.59%-13.90%+14.29%+36.17%-30.94%ALZNAlzamend Neuro-1.29%+0.44%+12.25%-43.87%-65.72%PASGPassage Bio+9.16%-6.67%+11.33%-24.83%-38.93%SNSESensei Biotherapeutics-5.43%-35.00%-48.62%-66.57%+65.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.91-0.5%$1.84$1.26▼$4.50$16.37M2.411.05 million shs25,851 shsALZNAlzamend Neuro$1.21+5.7%$1.08$0.84▼$3.60$4.36M0.1661,535 shs61,212 shsPASGPassage Bio$5.81+3.8%$6.51$3.93▼$20.00$17.96M1.4134,730 shs30,356 shsSNSESensei Biotherapeutics$13.00+20.5%$23.28$5.60▼$36.76$14.48M-0.2544,130 shs58,044 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+1.59%-13.90%+14.29%+36.17%-30.94%ALZNAlzamend Neuro-1.29%+0.44%+12.25%-43.87%-65.72%PASGPassage Bio+9.16%-6.67%+11.33%-24.83%-38.93%SNSESensei Biotherapeutics-5.43%-35.00%-48.62%-66.57%+65.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/AALZNAlzamend Neuro 2.00Hold$28.002,214.05% UpsidePASGPassage Bio 2.11Hold$13.25128.06% UpsideSNSESensei Biotherapeutics 2.43Hold$48.00269.23% UpsideCurrent Analyst Ratings BreakdownLatest ALZN, PASG, AIMD, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/11/2026SNSESensei Biotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.006/10/2026PASGPassage Bio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral6/10/2026PASGPassage Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/4/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/28/2026SNSESensei Biotherapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$50.005/26/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026SNSESensei Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.005/21/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/8/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$120K135.61N/AN/A$1.29 per share1.48ALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/APASGPassage BioN/AN/AN/AN/A$5.90 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$2.89N/AN/AN/A-11,912.10%-160.55%-62.29%N/AALZNAlzamend Neuro-$4.51M-$2.16N/AN/AN/AN/A-177.52%-140.41%7/28/2026 (Estimated)PASGPassage Bio-$45.52M-$11.84N/AN/AN/AN/A-150.88%-59.78%7/30/2026 (Estimated)SNSESensei Biotherapeutics-$21.08M-$142.72N/AN/AN/AN/A-83.59%-256.50%8/4/2026 (Estimated)Latest ALZN, PASG, AIMD, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A5/13/2026Q1 2026AIMDAinosN/A-$0.41N/A-$0.41N/AN/A5/12/2026Q1 2026PASGPassage Bio-$2.7640-$2.36+$0.4040-$2.36N/AN/A3/30/2026Q4 2025AIMDAinosN/A-$0.85N/A-$0.85N/AN/A3/30/2026Q4 2025SNSESensei Biotherapeutics-$4.81-$3.74+$1.07-$3.74($4.85) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AALZNAlzamend NeuroN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.580.550.50ALZNAlzamend NeuroN/A1.991.99PASGPassage BioN/A1.731.73SNSESensei BiotherapeuticsN/A14.3914.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AALZNAlzamend Neuro49.61%PASGPassage Bio53.48%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%ALZNAlzamend Neuro1.39%PASGPassage Bio4.90%SNSESensei Biotherapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos408.52 million7.69 millionNot OptionableALZNAlzamend Neuro43.80 million3.75 millionNo DataPASGPassage Bio1303.21 million3.05 millionNo DataSNSESensei Biotherapeutics401.34 million1.25 millionNot OptionableALZN, PASG, AIMD, and SNSE HeadlinesRecent News About These CompaniesSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2026 | businesswire.comMost and least shorted healthcare stocks with market cap up to $2B at the end of MayJune 3, 2026 | seekingalpha.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 25,000 Shares of StockJune 3, 2026 | americanbankingnews.comInsider Selling: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells 25,000 Shares of StockJune 2, 2026 | insidertrades.comCantor Fitzgerald initiates coverage of Sensei Biotherapeutics (SNSE) with overweight recommendationMay 30, 2026 | msn.comCitigroup initiates coverage of Sensei Biotherapeutics (SNSE) with buy recommendationMay 24, 2026 | msn.comSensei Biotherapeutics Updates 2026 Board Reconstitution PlansMay 22, 2026 | tipranks.comMillennium management reports $89k Sensei Biotherapeutics share salesMay 17, 2026 | investing.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $164,021.22 in StockMay 16, 2026 | insidertrades.comSensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | businesswire.comSensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsMay 5, 2026 | finance.yahoo.comSensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerMay 5, 2026 | businesswire.comSensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00April 28, 2026 | msn.comSensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | businesswire.comSensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | businesswire.comSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2026 | businesswire.comMerger deal renews Faeth in Sensei; Piktor brightens, stock jumpsFebruary 18, 2026 | bioworld.comBSensei Biotherapeutics stock soars after Faeth Therapeutics acquisitionFebruary 18, 2026 | investing.comSensei Biotherapeutics stock soars 230% after Faeth dealFebruary 18, 2026 | msn.comSensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private PlacementFebruary 18, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALZN, PASG, AIMD, and SNSE Company DescriptionsAinos NASDAQ:AIMD$1.91 -0.01 (-0.52%) Closing price 04:00 PM EasternExtended Trading$1.84 -0.08 (-3.93%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Alzamend Neuro NASDAQ:ALZN$1.21 +0.07 (+5.68%) Closing price 04:00 PM EasternExtended Trading$1.17 -0.04 (-3.22%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Passage Bio NASDAQ:PASG$5.81 +0.21 (+3.75%) Closing price 04:00 PM EasternExtended Trading$5.76 -0.05 (-0.86%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Sensei Biotherapeutics NASDAQ:SNSE$13.00 +2.21 (+20.48%) Closing price 04:00 PM EasternExtended Trading$12.97 -0.03 (-0.23%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
